Drug Trial Radar · NCT02970162
Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)
Last checked: Nov 20, 2026Latest source record: Dec 24, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
26
Actual
Start
Nov 2016
Primary completion
Oct 2017
Study completion Oct 2017
Sponsor
- Lead sponsor
- Catalyst Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 21, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates the effect of withdrawing amifampridine phosphate treatment from patients with LEMS. One half of the patients will continue to receive amifampridine phosphate and the other half will receive placebo, during this double-blind study.
Conditions
- Lambert-Eaton Myasthenic Syndrome
Interventions
Amifampridine PhosphateDrug
Placebo Oral TabletDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Quantitative Myasthenia Gravis (QMG) ScoreTime frame: change from baseline in QMG score at end of day 4
- Subject Global Impression (SGI) ScoreTime frame: change from baseline in SGI score at end of day 4
Locations
1 site in 1 country. Site status is shown where the registry gives one.
UCLA
Los Angeles, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.